BRAIN BIOTECH AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.88 EUR | +4.73% |
|
+0.70% | -21.31% |
Valuation
| Fiscal Period: September | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 216.3 | 141 | 220.7 | 96.35 | 92.63 | 62.92 | - | - |
| Enterprise Value (EV) 1 | 229.3 | 152.3 | 217 | 111.8 | 116.1 | 87.32 | 85.67 | 89.29 |
| P/E ratio | -20.7 x | -13.7 x | -40.4 x | -14.7 x | -11.2 x | -17.2 x | -21.2 x | 28.7 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 5.6 x | 3.6 x | 5.75 x | 1.95 x | 1.67 x | 0.97 x | 0.83 x | 0.8 x |
| EV / Revenue | 5.94 x | 3.89 x | 5.65 x | 2.26 x | 2.1 x | 1.35 x | 1.13 x | 1.13 x |
| EV / EBITDA | -109 x | -76.2 x | -86.8 x | -85.4 x | -141 x | 48.7 x | 14.2 x | 7.36 x |
| EV / FCF | -22.9 x | -20 x | -42 x | -14.8 x | -16.9 x | -54.6 x | -57.1 x | 89.3 x |
| FCF Yield | -4.37% | -5.01% | -2.38% | -6.77% | -5.9% | -1.83% | -1.75% | 1.12% |
| Price to Book | 17.7 x | 6.78 x | 5.69 x | 3.25 x | 4.25 x | 3.17 x | 3.06 x | 4 x |
| Nbr of stocks (in thousands) | 18,056 | 19,861 | 21,847 | 21,847 | 21,847 | 21,847 | - | - |
| Reference price 2 | 11.98 | 7.100 | 10.10 | 4.410 | 4.240 | 2.880 | 2.880 | 2.880 |
| Announcement Date | 1/14/20 | 1/14/21 | 1/17/22 | 1/16/23 | 1/17/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: September | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 38.6 | 39.2 | 38.4 | 49.5 | 55.34 | 64.79 | 75.94 | 78.8 |
| EBITDA 1 | -2.1 | -2 | -2.5 | -1.309 | -0.826 | 1.793 | 6.038 | 12.13 |
| EBIT 1 | -7.2 | -8.229 | -6.548 | -5.648 | -5.48 | -1.657 | 0.7548 | 6.658 |
| Operating Margin | -18.65% | -20.99% | -17.05% | -11.41% | -9.9% | -2.56% | 0.99% | 8.45% |
| Earnings before Tax (EBT) 1 | -10.49 | -9.944 | -4.276 | -6.165 | -7.489 | -3.143 | -2.855 | 2.683 |
| Net income 1 | -10.48 | -9.684 | -4.972 | -6.59 | -8.279 | -5.79 | -2.913 | 2.233 |
| Net margin | -27.14% | -24.7% | -12.95% | -13.31% | -14.96% | -8.94% | -3.84% | 2.83% |
| EPS 2 | -0.5800 | -0.5200 | -0.2500 | -0.3000 | -0.3800 | -0.1670 | -0.1361 | 0.1004 |
| Free Cash Flow 1 | -10.02 | -7.626 | -5.168 | -7.567 | -6.856 | -1.6 | -1.5 | 1 |
| FCF margin | -25.95% | -19.45% | -13.46% | -15.29% | -12.39% | -2.47% | -1.98% | 1.27% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | 8.25% |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | 44.78% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 1/14/20 | 1/14/21 | 1/17/22 | 1/16/23 | 1/17/24 | - | - | - |
1EUR in Million2EUR
Estimates
Balance Sheet Analysis
| Fiscal Period: September | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 13 | 11.3 | - | 15.4 | 23.5 | 24.4 | 22.8 | 26.4 |
| Net Cash position 1 | - | - | 3.7 | - | - | - | - | - |
| Leverage (Debt/EBITDA) | -6.193 x | -5.662 x | - | -11.79 x | -28.42 x | 13.61 x | 3.768 x | 2.174 x |
| Free Cash Flow 1 | -10 | -7.63 | -5.17 | -7.57 | -6.86 | -1.6 | -1.5 | 1 |
| ROE (net income / shareholders' equity) | -58.6% | -53.6% | -16.7% | -19.3% | -32.2% | -30.6% | -20.4% | 15.7% |
| ROA (Net income/ Total Assets) | -14.9% | -14% | -6.63% | -8.46% | -11.1% | -9.02% | -4.51% | 5.54% |
| Assets 1 | 70.29 | 69.14 | 74.95 | 77.86 | 74.46 | 64.21 | 64.63 | 40.32 |
| Book Value Per Share 2 | 0.6800 | 1.050 | 1.780 | 1.360 | 1.000 | 0.9100 | 0.9400 | 0.7200 |
| Cash Flow per Share 2 | -0.1900 | -0.2600 | -0.2000 | -0.0700 | -0.1900 | -0.1400 | 0 | 0.3500 |
| Capex 1 | 6.64 | 2.86 | 1.26 | 6.08 | 2.62 | 3.2 | 3.15 | 3 |
| Capex / Sales | 17.19% | 7.29% | 3.29% | 12.29% | 4.73% | 4.94% | 4.15% | 3.81% |
| Announcement Date | 1/14/20 | 1/14/21 | 1/17/22 | 1/16/23 | 1/17/24 | - | - | - |
1EUR in Million2EUR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.88
EUR
Average target price
10.98
EUR
Spread / Average Target
+281.08%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -21.31% | 67.17M | |
| -29.08% | 213M |
- Stock Market
- Equities
- BNN Stock
- Financials BRAIN Biotech AG
